| Nov 5 |
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 5 |
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
|
| Nov 4 |
Affimed files for $20M mixed securities shelf
|
| Oct 24 |
683 Capital Management, LLC Expands Stake in Affimed NV
|
| Sep 10 |
Affimed to Present at the Cantor Global Healthcare Conference 2024
|
| Sep 5 |
Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript
|
| Sep 5 |
Affimed N.V. 2024 Q2 - Results - Earnings Call Presentation
|
| Sep 5 |
Affimed N.V.: Q2 Earnings Snapshot
|
| Sep 5 |
Affimed GAAP EPS of -€1.01, revenue of €0.2M
|
| Sep 5 |
Affimed Reports Second Quarter 2024 Financial Results & Business Update
|
